Cargando…

Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study

OBJECTIVE: The prognosis of high‐risk metastatic hormone‐naïve prostate cancer is poor, and real‐world evidence of therapeutic options and sequences is lacking. The J‐ROCK study aimed to evaluate the outcomes in a real‐world setting in Japan. METHODS: Patients with high‐risk metastatic hormone‐naïve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uemura, Hirotsugu, Matsumoto, Rikiya, Mizokami, Atsushi, Miyake, Hideaki, Uemura, Hiroji, Matsuyama, Hideyasu, Nakamura, Kazuyoshi, Saito, Kazutaka, Kawakita, Mutsushi, Takeshita, Hideki, Koroki, Yosuke, Ono, Shintaro, Murota, Maiko, Ito, Miku, Kamoto, Toshiyuki, Fujimoto, Kiyohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles: Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540816/ https://www.ncbi.nlm.nih.gov/pubmed/36018236 http://dx.doi.org/10.1111/iju.14993

Ejemplares similares

Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma
por: Yoshida, Takashi, et al.
Publicado: (2020)

Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Bladder cancer prospective cohort study on high‐risk non‐muscle invasive bladder cancer after photodynamic diagnosis‐assisted transurethral resection of the bladder tumor (BRIGHT study)
por: Kobayashi, Keita, et al.
Publicado: (2022)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma
por: Miyake, Makito, et al.
Publicado: (2019)

Comparison of the Safety and Efficacy of Photoselective Vaporization of the Prostate (PVP) and Transurethral Enucleation with a Bipolar System (TUEB): A Single-Center Retrospective Study
por: Kiba, Keisuke, et al.
Publicado: (2020)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
por: Hinata, Nobuyuki, et al.
Publicado: (2020)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study
por: Inamoto, Teruo, et al.
Publicado: (2018)

Editorial Comment to A case of perirenal non‐specific lymphadenitis mimicking a solitary renal mass
por: Kubota, Masashi, et al.
Publicado: (2021)

Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: A case report
por: Tohi, Yoichiro, et al.
Publicado: (2019)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

The Utility and Limitations of Contrast-Enhanced Ultrasound for the Diagnosis and Treatment of Prostate Cancer
por: Sano, Futoshi, et al.
Publicado: (2015)

Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non‐muscle‐invasive bladder cancer: A comparative study from experienced institutes
por: Miyake, Makito, et al.
Publicado: (2023)

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
por: Nagao, Kazuhiro, et al.
Publicado: (2016)

The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
por: Uemura, Hiroji, et al.
Publicado: (2022)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Pretreatment assessment and perioperative nutritional interventions for patients with bladder cancer undergoing radical cystectomy
por: Miyake, Makito, et al.
Publicado: (2018)

The impact of smoking on male lower urinary tract symptoms (LUTS)
por: Kawahara, Takashi, et al.
Publicado: (2020)

Re: Geriatric 8 screening of frailty in patients with prostate cancer
por: Sugimura, Rumiko, et al.
Publicado: (2020)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019)

Arterial aneurysmal sac-ureteral fistula after aortic and common iliac aneurysmal repair: A case report
por: Makita, Noriyuki, et al.
Publicado: (2023)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2013)

Pericyte‐derived bone morphogenetic protein 4 underlies white matter damage after chronic hypoperfusion
por: Uemura, Maiko T., et al.
Publicado: (2017)

Association of PSA variability with prostate cancer development using large-scale medical information data: a retrospective cohort study
por: Maeda-Minami, Ayako, et al.
Publicado: (2023)

Nodular Development of Spontaneous Epithelial Thymoma in (ACI/NMs × BUF/Mna)F1 Rats
por: Matsuyama, Mutsushi, et al.
Publicado: (1988)

Sarcomatoid Variant of Bladder Carcinoma: A Case Report
por: Uemura, Koichi, et al.
Publicado: (2018)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer
por: Suzuki, Hiroyoshi, et al.
Publicado: (2019)

The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday
por: Kawahara, Takashi, et al.
Publicado: (2019)

Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
por: Kawahara, Takashi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_835fk9rk29pcbnm9qgp5uo8b57